BridgeBio Pharma (NASDAQ:BBIO) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Posted by Casey Walker on Apr 9th, 2026

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO). In a filing disclosed on April 07th, the Representative disclosed that they had bought between $1,001 and $15,000 in BridgeBio Pharma stock on March 19th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

BridgeBio Pharma Stock Up 1.9%

NASDAQ:BBIO traded up $1.38 on Thursday, reaching $75.52. The company’s stock had a trading volume of 2,408,599 shares, compared to its average volume of 2,750,284. BridgeBio Pharma, Inc. has a 12-month low of $30.08 and a 12-month high of $84.94. The firm has a market cap of $14.64 billion, a price-to-earnings ratio of -19.98 and a beta of 1.09. The stock has a 50 day moving average price of $71.05 and a 200 day moving average price of $68.51.

BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last posted its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The business had revenue of $154.18 million during the quarter, compared to the consensus estimate of $150.71 million. During the same quarter in the prior year, the company earned ($1.40) EPS. The firm’s revenue for the quarter was up 2521.2% on a year-over-year basis. Equities research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Insider Activity

In related news, Director Andrea Ellis sold 64,921 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $64.87, for a total transaction of $4,211,425.27. Following the completion of the transaction, the director directly owned 18,589 shares of the company’s stock, valued at $1,205,868.43. The trade was a 77.74% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Maricel Apuli sold 510 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.31, for a total value of $37,898.10. Following the transaction, the chief accounting officer directly owned 123,945 shares of the company’s stock, valued at $9,210,352.95. The trade was a 0.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 197,084 shares of company stock worth $13,649,619 over the last three months. Company insiders own 18.20% of the company’s stock.

Institutional Investors Weigh In On BridgeBio Pharma

Institutional investors and hedge funds have recently modified their holdings of the company. Brooklands Fund Management Ltd acquired a new position in BridgeBio Pharma during the 4th quarter worth $210,348,000. Price T Rowe Associates Inc. MD grew its stake in BridgeBio Pharma by 144.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 3,828,746 shares of the company’s stock worth $292,862,000 after purchasing an additional 2,261,181 shares in the last quarter. Janus Henderson Group PLC grew its stake in BridgeBio Pharma by 25.8% during the 4th quarter. Janus Henderson Group PLC now owns 11,000,457 shares of the company’s stock worth $841,349,000 after purchasing an additional 2,259,378 shares in the last quarter. Norges Bank acquired a new position in BridgeBio Pharma during the 4th quarter worth $116,802,000. Finally, Wellington Management Group LLP grew its stake in BridgeBio Pharma by 130.4% during the 4th quarter. Wellington Management Group LLP now owns 2,348,731 shares of the company’s stock worth $179,654,000 after purchasing an additional 1,329,537 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. Wells Fargo & Company lifted their target price on BridgeBio Pharma from $88.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, February 13th. Sanford C. Bernstein started coverage on BridgeBio Pharma in a report on Thursday, December 11th. They issued an “outperform” rating and a $94.00 price objective on the stock. Truist Financial boosted their price objective on BridgeBio Pharma from $86.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Mizuho boosted their price objective on BridgeBio Pharma from $91.00 to $106.00 and gave the company an “outperform” rating in a report on Wednesday, March 18th. Finally, Royal Bank Of Canada started coverage on BridgeBio Pharma in a report on Thursday. They issued an “outperform” rating and a $100.00 price objective on the stock. Twenty-four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $87.38.

View Our Latest Report on BBIO

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About BridgeBio Pharma

(Get Free Report)

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.